CLADIBIOR
Tuberculosis Research
CLADIBIOR is evaluating and validating newly discovered tuberculosis (TB) biomarkers as signatures for monitoring protective immunity against TB. Specifically, we propose:
-
To determine at the single cell level cytokine production, cellular phenotypes and function of M. tuberculosis-specific CD4 and CD8 memory T cells by multiparameter flow cytometry and ICS in the specific response to M. tuberculosis antigens.
-
To analyse patterns of M. tuberculosis antigen-induced multiplex cytokine, chemokine and cytotoxic molecule production.
-
To assess these responses in well-defined cohorts of M. tuberculosis-infected or exposed individuals and patients with active TB either or not co-infected with HIV, and follow up longitudinally after anti-tuberculosis chemotherapy, in order to correlate specific responses with protective immunity.
Evaluating and validating newly discovered tuberculosis (TB) biomarkers as signatures for monitoring protective immunity against TB.
Characterizing γδ T cell subsets and exploring immune regulation in autoimmunity and host defense from pathogens.
Boosting immune response against cancer cells.
Partner of a scientific network, promoting excellence in immunology research.
Cellular Immunology
CLADIBIOR investigates γδ T cells, a subset of T cells that express a unique T-cell receptor (TCR) composed of one γ-chain and one δ-chain. Gammadelta T cells are of low abundance in the body, are found in the gut mucosa, skin, lungs and uterus, and are involved in the initiation and propagation of immune responses. In addition, γδ T cells have unique specificities, high clonal frequencies and a pre-activated differentiation status that allow rapid and non-redundant responses to tumours.
Moreover, our Lab is interested in elucidating mechanisms of autoimmunity in Rheumatoid Arthritis, Sjögren syndrome, Multiple Sclerosis and other autoimmune diseases.
Cancer immunotherapy
The past few decades have seen a groundswell of research on the immune system yielding a deeper understanding of how cancer progresses and offering new ways to stop it. Our Lab is evaluating a range of cancer therapies that exploit the complex interactions between tumours and immune cells.
